These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25986690)

  • 21. Allosteric inhibition of g-protein coupled receptor oligomerization: strategies and challenges for drug development.
    Hurevich M; Talhami A; Shalev DE; Gilon C
    Curr Top Med Chem; 2014; 14(15):1842-63. PubMed ID: 25175995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacophore modelling as a virtual screening tool for the discovery of small molecule protein-protein interaction inhibitors.
    Voet A; Zhang KY
    Curr Pharm Des; 2012; 18(30):4586-98. PubMed ID: 22650262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Small-Molecule Stabilization of the 14-3-3/Gab2 Protein-Protein Interaction (PPI) Interface.
    Bier D; Bartel M; Sies K; Halbach S; Higuchi Y; Haranosono Y; Brummer T; Kato N; Ottmann C
    ChemMedChem; 2016 Apr; 11(8):911-8. PubMed ID: 26644359
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AlphaSpace: Fragment-Centric Topographical Mapping To Target Protein-Protein Interaction Interfaces.
    Rooklin D; Wang C; Katigbak J; Arora PS; Zhang Y
    J Chem Inf Model; 2015 Aug; 55(8):1585-99. PubMed ID: 26225450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The potential role of in silico approaches to identify novel bioactive molecules from natural resources.
    Olğaç A; Orhan IE; Banoglu E
    Future Med Chem; 2017 Sep; 9(14):1665-1686. PubMed ID: 28841048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hot spot analysis for driving the development of hits into leads in fragment-based drug discovery.
    Hall DR; Ngan CH; Zerbe BS; Kozakov D; Vajda S
    J Chem Inf Model; 2012 Jan; 52(1):199-209. PubMed ID: 22145575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and screening of small-molecule α-helix mimetic libraries targeting protein-protein interactions.
    Moon H; Lim HS
    Curr Opin Chem Biol; 2015 Feb; 24():38-47. PubMed ID: 25461722
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules.
    Daina A; Michielin O; Zoete V
    Nucleic Acids Res; 2019 Jul; 47(W1):W357-W364. PubMed ID: 31106366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Motif mediated protein-protein interactions as drug targets.
    Corbi-Verge C; Kim PM
    Cell Commun Signal; 2016 Mar; 14():8. PubMed ID: 26936767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Small molecules, big targets: drug discovery faces the protein-protein interaction challenge.
    Scott DE; Bayly AR; Abell C; Skidmore J
    Nat Rev Drug Discov; 2016 Aug; 15(8):533-50. PubMed ID: 27050677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biology-oriented synthesis: harnessing the power of evolution.
    van Hattum H; Waldmann H
    J Am Chem Soc; 2014 Aug; 136(34):11853-9. PubMed ID: 25074019
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging roles of allosteric modulators in the regulation of protein-protein interactions (PPIs): A new paradigm for PPI drug discovery.
    Ni D; Lu S; Zhang J
    Med Res Rev; 2019 Nov; 39(6):2314-2342. PubMed ID: 30957264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mass spectrometry for fragment screening.
    Chan DS; Whitehouse AJ; Coyne AG; Abell C
    Essays Biochem; 2017 Nov; 61(5):465-473. PubMed ID: 28986384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protein-protein interactions: network analysis and applications in drug discovery.
    Bultinck J; Lievens S; Tavernier J
    Curr Pharm Des; 2012; 18(30):4619-29. PubMed ID: 22650261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Small-molecule protein-protein interaction inhibitors: therapeutic potential in light of molecular size, chemical space, and ligand binding efficiency considerations.
    Buchwald P
    IUBMB Life; 2010 Oct; 62(10):724-31. PubMed ID: 20979208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulating protein-protein interactions: from structural determinants of binding to druggability prediction to application.
    Metz A; Ciglia E; Gohlke H
    Curr Pharm Des; 2012; 18(30):4630-47. PubMed ID: 22650257
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular recognition of ternary complexes: a new dimension in the structure-guided design of chemical degraders.
    Hughes SJ; Ciulli A
    Essays Biochem; 2017 Nov; 61(5):505-516. PubMed ID: 29118097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of Amino Acid Mutations and Small Molecules on Targeted Inhibition of Proteins Involved in Cancer.
    Kanakaveti V; Anoosha P; Sakthivel R; Rayala SK; Gromiha MM
    Curr Top Med Chem; 2019; 19(6):457-466. PubMed ID: 30836917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Importance of Rigidity in Designing Small Molecule Drugs To Tackle Protein-Protein Interactions (PPIs) through Stabilization of Desired Conformers.
    Lawson ADG; MacCoss M; Heer JP
    J Med Chem; 2018 May; 61(10):4283-4289. PubMed ID: 29140691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting Protein-Protein Interaction with Covalent Small-Molecule Inhibitors.
    Li B; Rong D; Wang Y
    Curr Top Med Chem; 2019; 19(21):1872-1876. PubMed ID: 31696799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.